U.S. Markets close in 3 hrs 14 mins

Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update

DUBLIN, Sept. 18, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will host a webcast on Wednesday, September 25, 2019 at 9:00 p.m. EDT/2:00 a.m. IST (September 26, 2019) to provide investors with a business update, including data being presented on JZP-258 and solriamfetol at the World Sleep Congress, to be held in Vancouver, B.C. September 20-25, 2019.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least one week.

Audio webcast/conference call:
U.S. Dial-In Number:  +1 855 353 7924
International Dial-In Number: +1 503 343 6056
Passcode: 4685113

A replay of the conference call will be available through October 2, 2019 and accessible through one of the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 855 859 2056
Replay International Dial-In Number:  +1 404 537 3406
Passcode: 4685113

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options.  As a leader in sleep medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical discoveries into novel medicines.  Jazz Pharmaceuticals markets SunosiTM (solriamfetol), Xyrem® (sodium oxybate) oral solution, Defitelio® (defibrotide sodium), Erwinaze® (asparaginase Erwinia chrysanthemi) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Defitelio® (defibrotide), Erwinase® and Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S.  For country-specific product information, please visit www.jazzpharmaceuticals.com/medicines.  For more information, please visit www.jazzpharmaceuticals.com and follow us on Twitter at @JazzPharma.

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

 

Jazz Pharmaceuticals Contacts:


Investors: 
Kathee Littrell
Vice President, Investor Relations
Ireland, +353 1 634 7887
U.S., +1 650 496 2717

Media:
Jacqueline Kirby
Vice President, Corporate Affairs & Government Relations
Ireland, +353 1 697 2141
U.S., +1 215 867 4910


 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-webcast-for-world-sleep-congress-investor-update-300921051.html